Universität zu Köln

Ceccon, Garry, Werner, Jan-Michael, Dunkl, Veronika, Tscherpel, Caroline, Stoffels, Gabriele, Brunn, Anna ORCID: 0000-0001-6233-8339, Deckert, Martina, Fink, Gereon R. ORCID: 0000-0002-8230-1856 and Galldiks, Norbert ORCID: 0000-0002-2485-1796 (2018). Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. Int. J. Mol. Sci., 19 (4). BASEL: MDPI. ISSN 1422-0067

Full text not available from this repository.

Abstract

Novel therapeutic targets in malignant glioma patients are urgently needed. Point mutations of the v-Raf murine sarcoma viral oncogene homolog B (BRAF) gene occur predominantly in melanoma patients, but may also occur in gliomas. Thus, this is a target of great interest for this group of patients. In a nine-year-old male patient, an anaplastic astrocytoma in the left temporoparietal region was diagnosed histologically. After first-and second-line treatment, a malignant progression to a secondary glioblastoma was observed ten years after the initial diagnosis. Within the following seven years, all other conventional treatment options were exhausted. At this time point, recurrent tumor histology revealed an epithelioid glioblastoma, without a mutation in the isocitrate dehydrogenase gene (IDH wild-type). In order to identify a potential target for an experimental salvage therapy, mutational tumor analysis showed a BRAF V600E mutation. Consecutively, dabrafenib treatment was initiated. The patient remained clinically stable, and follow-up magnetic resonance images (MRI) were consistent with Stable Disease according to the Response Assessment in Neuro-Oncology Working Group (RANO) criteria for the following ten months until tumor progression was detected. The patient died 16 months after dabrafenib treatment initiation. Particularly in younger glioma patients as well as in patients with an epithelioid glioblastoma, screening for a V600E BRAF mutation is promising since, in these cases, targeted therapy with BRAF inhibitors seems to be a useful salvage treatment option.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Ceccon, Garry UNSPECIFIED UNSPECIFIED UNSPECIFIED Werner, Jan-Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Dunkl, Veronika UNSPECIFIED UNSPECIFIED UNSPECIFIED Tscherpel, Caroline UNSPECIFIED UNSPECIFIED UNSPECIFIED Stoffels, Gabriele UNSPECIFIED UNSPECIFIED UNSPECIFIED Brunn, Anna UNSPECIFIED orcid.org/0000-0001-6233-8339 UNSPECIFIED Deckert, Martina UNSPECIFIED UNSPECIFIED UNSPECIFIED Fink, Gereon R. UNSPECIFIED orcid.org/0000-0002-8230-1856 UNSPECIFIED Galldiks, Norbert UNSPECIFIED orcid.org/0000-0002-2485-1796 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-190007
DOI:	10.3390/ijms19041090
Journal or Publication Title:	Int. J. Mol. Sci.
Volume:	19
Number:	4
Date:	2018
Publisher:	MDPI
Place of Publication:	BASEL
ISSN:	1422-0067
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language RANDOMIZED CONTROLLED-TRIAL; CENTRAL-NERVOUS-SYSTEM; PLEOMORPHIC XANTHOASTROCYTOMA; METASTATIC MELANOMA; DIFFUSE ASTROCYTOMA; PLUS TRAMETINIB; DOUBLE-BLIND; OPEN-LABEL; GLIOMAS; TEMOZOLOMIDE Multiple languages Biochemistry & Molecular Biology; Chemistry, Multidisciplinary Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/19000